OCGN
Ocugen Inc
NASDAQ · Biotechnology
$1.33
+0.00 (+0.00%)
Open$1.36
Previous Close$1.33
Day High$1.39
Day Low$1.32
52W High$1.96
52W Low$0.52
Volume—
Avg Volume4.05M
Market Cap436.09M
P/E Ratio—
EPS$-0.22
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+2,153.4% upside
Current
$1.33
$1.33
Target
$29.97
$29.97
$22.68
$29.97 avg
$39.58
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 4.92M | 214.85M | 205.76M |
| Net Income | -65,413,732 | -16,849,465 | -19,542,916 |
| Profit Margin | -1,333.0% | -7.8% | -9.5% |
| EBITDA | -63,020,147 | -26,350,714 | -23,624,019 |
| Free Cash Flow | — | -15,177,197 | -13,829,123 |
| Rev Growth | +366.3% | +3.8% | +8.3% |
| Debt/Equity | 0.97 | 0.42 | 0.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |